Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Synergy To Acquire Callisto | Contract Pharma

What are you searching for?

Sign in
Breaking News

Synergy To Acquire Callisto

Gains portfolio of GI drug candidates

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Synergy Pharmaceuticals has entered into a definitive merger agreement, to acquire Callisto Pharmaceuticals. At closing, Callisto stockholders will own approximately 38.3% of the combined company, and Synergy stockholders will own approximately 61.7%. The transaction, subject to regulatory approvals and certain other conditions, is expected to close by the end of October.
 
Callisto is a biopharma company focused on the development of drugs to treat GI disorders and diseases. Callisto’s drug candidates, plecanatide and SP-333 to treat GI disorders and diseases, are being developed exclusively by Synergy.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters